Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017

Latest news articles

Added 5 days ago Drug news

FDA approves Supplemental New Drug Application for Spiriva Respimat (tiotropium bromide) in asthma in people age 6 and older- Boehringer

Boehringer announced that the FDA approved Spiriva Respimat (tiotropium bromide) for the long-term, once-daily maintenance treatment of asthma in people...

Added 5 days ago Drug news

FDA approves Siliq (brodalumab) to treat moderate-to-severe plaque psoriasis.-Valeant Pharma Intl.

The FDA has approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq...

Added 18 days ago Drug news

European Patent Office invalidates Sprycel (dasatinib) composition of matter patent.- BMS

BMS announced that the European Patent Office (EPO) upheld a decision with regard to European Patent No. 1169038 (the '038...

View all news articles

 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)

Cystic Fibrosis

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines

Visit Cystic Fibrosis

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal

 

Guidelines

Adalimumab for treating moderate to severe hidradenitis suppurativa

Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

Added 7 days ago

Guidelines of care for the management of psoriasis and psoriatic arthritis

Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Added 9 days ago

Canadian Guidelines for the Management of Plaque Psoriasis 2009

Since the publication of the 2009 Canadian Guidelines for the Management of Plaque Psoriasis, significant advances have been made in determining the role of T cells in inflammatory and autoimmune diseases. 

Added 9 days ago

View all guidelines

Journal articles

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.

Allergic rhinitis represents a global health problem affecting 10% to 20% of the population.

Added 6 minutes ago

Allergic rhinitis and its impact on asthma (ARIA) 2008.

Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure by an immunoglobulin E (IgE)-mediated inflammation of the membranes lining the nose.

Added 16 minutes ago

Influence of comorbid conditions on asthma.

Various conditions such as rhinosinusitis, gastro-oesophageal reflux disease, psychological disturbances, chronic infections and obstructive sleep apnoea are often observed in asthmatic patients and may affect asthma control and outcomes.

Added 29 minutes ago

View all journal articles

Clinical trials

A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

Hidradenitis Suppurativa is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring.

Added 7 days ago

Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study) (SHARPS)

The objective of this study is to assess the safety and efficacy of adalimumab prior to surgery in subjects with moderate to severe Hidradenitis Suppurativa (HS) who are surgical candidates.

Added 7 days ago

To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa (HIDRI2007)

The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg)

Added 7 days ago

View all clinical trials

Blog Posts

Antia Veiga Feijoo

Clinical Features and Treatment Of Acute Asthma Exacerbations

Posted 1 year ago

This post discusses clinical assessment and treatment of patients with acute asthma exacerbations.

Edzard Ernst

But he knows nothing about homeopathy!

Posted 1 year ago

Whenever I criticise their methods, homeopaths claim that my arguments are invalid because I know next to nothing about the subject. Is this because they feel threatened by my arguments? Or could it be that the allegation is incorrect?

You can judge for yourself - here is a (slightly shortened and revised) excerpt from my recent memoire ‘A SCIENTIST IN WONDERLAND’ which recounts my exposure to and experience in homeopathy.

Hugh Harvey

Metrics Madness

Posted 1 year ago

You shouldn't judge a book by its cover. That much is true, but it's also common sense not to judge a book by measuring the whiteness of its pages, or the amount of hamsters you can place on it. So why do we measure the fabulous NHS with nonsense metrics?